US6974796B1
(en)
|
1999-08-17 |
2005-12-13 |
Girsh Leonard S |
Therapeutic compositions for treatment of a damaged tissue
|
US5552412A
(en)
*
|
1995-01-09 |
1996-09-03 |
Pfizer Inc |
5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
|
UA51676C2
(uk)
*
|
1995-11-02 |
2002-12-16 |
Пфайзер Інк. |
(-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
|
TW442286B
(en)
*
|
1996-02-28 |
2001-06-23 |
Pfizer |
New therapeutic uses of estrogen agonists
|
IL120265A0
(en)
*
|
1996-02-28 |
1997-06-10 |
Pfizer |
Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
|
HN1996000101A
(es)
*
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
IL120266A
(en)
|
1996-02-28 |
2005-05-17 |
Pfizer |
Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
|
CA2206752A1
(en)
*
|
1996-07-02 |
1998-01-02 |
George Joseph Cullinan |
Benzothiophene compounds, intermediates, processes, and methods of use
|
ID19392A
(id)
*
|
1996-08-29 |
1998-07-09 |
Lilly Co Eli |
Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
|
CA2215856A1
(en)
*
|
1996-09-26 |
1998-03-26 |
Eli Lilly And Company |
Dihydrobenzofluorene compounds, intermediates, compositions, and methods
|
CA2215647A1
(en)
*
|
1996-10-24 |
1998-04-24 |
Eli Lilly And Company |
Naphthyl compounds, compositions, and methods
|
US6034102A
(en)
*
|
1996-11-15 |
2000-03-07 |
Pfizer Inc |
Atherosclerosis treatment
|
CA2287244A1
(en)
*
|
1997-04-25 |
1998-11-05 |
Henry Uhlman Bryant |
Indene compounds having activity as serms
|
KR20010020378A
(ko)
*
|
1997-04-30 |
2001-03-15 |
피터 지. 스트링거 |
벤조티오펜의 제조 방법
|
CA2231013A1
(en)
*
|
1997-04-30 |
1998-10-30 |
Eli Lilly And Company |
Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
|
JP2001524114A
(ja)
*
|
1997-04-30 |
2001-11-27 |
イーライ・リリー・アンド・カンパニー |
ベンゾ[b]チオフェン類の製造における中間体および方法
|
WO1998048793A1
(en)
*
|
1997-04-30 |
1998-11-05 |
Eli Lilly And Company |
INTERMEDIATES AND PROCESSES FOR PREPARING BENZO[b]THIOPHENES
|
CA2236254A1
(en)
*
|
1997-04-30 |
1998-10-30 |
David Warren Hoard |
Process for preparing benzo¬b|thiophenes
|
KR20010020379A
(ko)
*
|
1997-04-30 |
2001-03-15 |
피터 지. 스트링거 |
치환된 벤조[b]티오펜을 제조하기 위한 레지오선택적 알킬화 방법
|
EP0895989B1
(en)
|
1997-08-07 |
2005-05-18 |
Eli Lilly And Company |
1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity
|
US5908859A
(en)
*
|
1997-08-11 |
1999-06-01 |
Eli Lilly And Company |
Benzothiophenes for inhibiting hyperlipidemia
|
US6107346A
(en)
*
|
1997-08-11 |
2000-08-22 |
Eli Lilly And Company |
Methods for treating hyperlipidemia
|
US6080773A
(en)
*
|
1997-10-14 |
2000-06-27 |
Akzo Nobel, N.V. |
Benzylamine derivatives which are useful in treating psychiatric disorders
|
US20020037885A1
(en)
*
|
1999-07-22 |
2002-03-28 |
Dijcks Fredericus Antonius |
Therapeutic compounds
|
AU3352899A
(en)
*
|
1997-12-11 |
1999-07-12 |
American Home Products Corporation |
2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof
|
US6384060B1
(en)
|
1997-12-11 |
2002-05-07 |
American Home Products Corporation |
2,4,6-trisbstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof
|
FR2778404B1
(fr)
*
|
1998-05-06 |
2000-06-30 |
Hoechst Marion Roussel Inc |
Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant
|
ES2220005T3
(es)
|
1998-06-16 |
2004-12-01 |
Pfizer Products Inc. |
Combinaciones terapeuticas que comprenden un modulador selectivo del receptor de estrogeno y prostaglandina e2.
|
PA8471201A1
(es)
*
|
1998-06-16 |
2000-09-29 |
Pfizer Prod Inc |
Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
|
DE19833786A1
(de)
*
|
1998-07-18 |
2000-01-20 |
Schering Ag |
Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
EP1004306A3
(en)
*
|
1998-08-06 |
2000-06-07 |
Pfizer Products Inc. |
Estrogen agonists/antagonists
|
US6503917B1
(en)
|
1998-12-10 |
2003-01-07 |
Wyeth, Five Giralda Farms |
2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof
|
US6331562B1
(en)
|
1998-12-30 |
2001-12-18 |
Signal Pharmaceuticals, Inc. |
Compounds and methods for modulation of estrogen receptors
|
US6291456B1
(en)
|
1998-12-30 |
2001-09-18 |
Signal Pharmaceuticals, Inc. |
Compounds and methods for modulation of estrogen receptors
|
AU766648B2
(en)
*
|
1999-03-17 |
2003-10-23 |
Axys Pharmaceuticals, Inc. |
Compounds and methods for modulation of estrogen receptors
|
US6593322B1
(en)
|
1999-03-17 |
2003-07-15 |
Signal Pharmaceuticals, Inc. |
Compounds and methods for modulation of estrogen receptors
|
US6391907B1
(en)
*
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
US6355648B1
(en)
*
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
YU26700A
(sh)
*
|
1999-05-24 |
2002-06-19 |
Pfizer Products Inc. |
Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
|
TR200502284T2
(tr)
*
|
1999-07-06 |
2005-08-22 |
Endorecherche, Inc. |
Kilo alımını tedavi ve/veya önleme metotları
|
EP1086692A3
(en)
*
|
1999-07-28 |
2003-07-09 |
Pfizer Products Inc. |
Estrogen agonists and antagonists for multiple indications
|
US20070037777A1
(en)
*
|
2005-08-12 |
2007-02-15 |
Immunopath Profile, Inc. |
Lipid-containing compositions and methods of using them
|
US7790678B1
(en)
|
1999-08-17 |
2010-09-07 |
Immunopath Profile, Inc. |
Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use
|
US6436977B1
(en)
*
|
1999-09-29 |
2002-08-20 |
Pfizer Inc. |
Dosing regimens for lasofoxifene
|
WO2001024826A2
(en)
*
|
1999-10-06 |
2001-04-12 |
The Brigham And Women's Hospital, Inc. |
Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
|
EP1113007A1
(en)
*
|
1999-12-24 |
2001-07-04 |
Pfizer Inc. |
Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
CO5271696A1
(es)
*
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
CO5251465A1
(es)
*
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
ATE333450T1
(de)
*
|
2000-04-07 |
2006-08-15 |
Pfizer Prod Inc |
Metabolite von estrogen-agonisten/-antagonisten
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
DE60124616T2
(de)
*
|
2000-05-08 |
2007-09-13 |
Pfizer Products Inc., Groton |
Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors
|
KR100795870B1
(ko)
*
|
2000-06-01 |
2008-01-21 |
왓슨 파머수티컬즈, 인코포레이티드 |
라소폭시펜의 경피적 송달
|
AR029538A1
(es)
|
2000-07-06 |
2003-07-02 |
Wyeth Corp |
Composiciones farmaceuticas de agentes estrogenicos
|
EP1192945A3
(en)
*
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
JP2002117407A
(ja)
*
|
2000-10-10 |
2002-04-19 |
Satake Corp |
動画像検索方法及びその装置
|
IL145838A
(en)
*
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
|
TWI303990B
(en)
|
2000-10-17 |
2008-12-11 |
Pfizer Prod Inc |
New use of estrogen agonists/antagonists for improving vascular health
|
ES2233570T3
(es)
*
|
2000-11-30 |
2005-06-16 |
Pfizer Products Inc. |
Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona.
|
US7256201B2
(en)
|
2000-12-07 |
2007-08-14 |
Astrazeneca Ab |
Selective estrogen receptor-β ligands
|
WO2002056903A2
(en)
*
|
2001-01-17 |
2002-07-25 |
Praecis Pharmaceuticals Inc. |
Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
US6599921B2
(en)
|
2001-02-22 |
2003-07-29 |
Nanodesign, Inc. |
Non-steroidal estrogen receptor ligands
|
AU2756602A
(en)
*
|
2001-04-25 |
2002-10-31 |
Pfizer Products Inc. |
Methods and kits for treating depression or preventing deterioration of cognitive function
|
US20020182646A1
(en)
*
|
2001-04-30 |
2002-12-05 |
Ke Huazhu |
Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
|
AP2003002900A0
(en)
*
|
2001-05-01 |
2003-12-31 |
Pfizer Prod Inc |
Method for manufacturing a low dose pharmaceutical composition
|
US7425565B2
(en)
*
|
2002-05-09 |
2008-09-16 |
Cedars-Sinai Medical Center |
Use of benzothiopenes to treat and prevent prostate cancer
|
TWI224101B
(en)
|
2001-06-20 |
2004-11-21 |
Wyeth Corp |
Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
|
DK1397130T3
(da)
|
2001-06-20 |
2007-11-12 |
Wyeth Corp |
Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
|
US7183410B2
(en)
*
|
2001-08-02 |
2007-02-27 |
Bidachem S.P.A. |
Stable polymorph of flibanserin
|
US20030060475A1
(en)
*
|
2001-08-10 |
2003-03-27 |
Boehringer Ingelheim Pharma Kg |
Method of using flibanserin for neuroprotection
|
EP1312363A1
(en)
*
|
2001-09-28 |
2003-05-21 |
Pfizer Products Inc. |
Methods of treatment and kits comprising a growth hormone secretagogue
|
US6884806B2
(en)
|
2001-10-17 |
2005-04-26 |
Bristol-Myers Squibb Company |
Bicyclic lactam derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
US20040214898A1
(en)
*
|
2001-11-29 |
2004-10-28 |
Steiner Mitchell S. |
Methods for treating hot flashes
|
US20040096510A1
(en)
*
|
2001-11-29 |
2004-05-20 |
Steiner Mitchell S. |
Prevention and treatment of androgen-deprivation induced osteoporosis
|
US20080249183A1
(en)
*
|
2001-11-29 |
2008-10-09 |
Steiner Mitchell S |
Treatment of androgen-deprivation induced osteoporosis
|
US20070197664A1
(en)
*
|
2001-11-29 |
2007-08-23 |
Steiner Mitchell S |
Prevention and treatment of androgen-deprivation induced osteoporosis
|
US20060269611A1
(en)
*
|
2001-11-29 |
2006-11-30 |
Steiner Mitchell S |
Prevention and treatment of androgen-deprivation induced osteoporosis
|
US20050080143A1
(en)
*
|
2001-11-29 |
2005-04-14 |
Steiner Mitchell S. |
Treatment of androgen-deprivation induced osteoporosis
|
US20040213841A1
(en)
*
|
2001-11-29 |
2004-10-28 |
Steiner Mitchell S |
Methods for treating hot flashes and gynecomastia
|
US7524866B2
(en)
*
|
2001-11-29 |
2009-04-28 |
Gtx, Inc. |
Prevention and treatment of androgen—deprivation induced osteoporosis
|
US7342884B2
(en)
*
|
2002-03-13 |
2008-03-11 |
Harmonic, Inc. |
Method and apparatus for one directional communications in bidirectional communications channel
|
RU2278861C2
(ru)
*
|
2002-03-28 |
2006-06-27 |
Пфайзер Продактс Инк. |
Очищенный лазофоксифен и способ очистки рацемического лазофоксифена рекристаллизацией
|
US20040048877A1
(en)
*
|
2002-05-22 |
2004-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions containing flibanserin
|
US6608212B1
(en)
*
|
2002-06-04 |
2003-08-19 |
Pfizer, Inc. |
Process for preparing vinylaromatic compounds
|
PA8576201A1
(es)
*
|
2002-07-10 |
2004-05-26 |
Pfizer Prod Inc |
Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
|
JP4656939B2
(ja)
|
2002-07-22 |
2011-03-23 |
イーライ リリー アンド カンパニー |
フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
|
US9315539B2
(en)
*
|
2002-10-01 |
2016-04-19 |
Yale University |
11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer
|
UA80453C2
(en)
|
2002-12-10 |
2007-09-25 |
|
Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
WO2004052854A2
(en)
|
2002-12-10 |
2004-06-24 |
Wyeth |
Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
CA2509170A1
(en)
|
2002-12-10 |
2004-06-24 |
Wyeth |
Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
DK1569900T3
(da)
|
2002-12-10 |
2006-10-23 |
Wyeth Corp |
Substituerede 3-carbonyl-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
AU2003296323A1
(en)
|
2002-12-10 |
2004-06-30 |
Wyeth |
Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
EP1577288B1
(en)
|
2002-12-26 |
2014-07-23 |
Eisai R&D Management Co., Ltd. |
Selective estrogen receptor modulators
|
US7332525B2
(en)
|
2003-01-17 |
2008-02-19 |
Castle Erik P |
Method of treatment of prostate cancer and composition for treatment thereof
|
JP2006516276A
(ja)
*
|
2003-01-22 |
2006-06-29 |
ファイザー・プロダクツ・インク |
エストロゲンアゴニスト/アンタゴニストを使用して、関節痛を治療または睡眠を改善する方法
|
US20070042040A1
(en)
*
|
2003-04-30 |
2007-02-22 |
Herve Porchet |
Methods and compositions using gonadotropin hormone releasing hormone
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
RU2331425C2
(ru)
*
|
2003-09-19 |
2008-08-20 |
Висконсин Эламнай Рисерч Фаундейшн (ВАРФ) |
Фармацевтические композиции и способы, включающие комбинации производных 2-алкилиден-19-нор-витамина d и агониста/антагониста эстрогенов
|
US7442805B2
(en)
|
2003-09-25 |
2008-10-28 |
Wyeth |
Substituted sulfonamide-indoles
|
US7268159B2
(en)
|
2003-09-25 |
2007-09-11 |
Wyeth |
Substituted indoles
|
US7265148B2
(en)
|
2003-09-25 |
2007-09-04 |
Wyeth |
Substituted pyrrole-indoles
|
US7582773B2
(en)
|
2003-09-25 |
2009-09-01 |
Wyeth |
Substituted phenyl indoles
|
US7342039B2
(en)
|
2003-09-25 |
2008-03-11 |
Wyeth |
Substituted indole oximes
|
US7411083B2
(en)
|
2003-09-25 |
2008-08-12 |
Wyeth |
Substituted acetic acid derivatives
|
US7446201B2
(en)
|
2003-09-25 |
2008-11-04 |
Wyeth |
Substituted heteroaryl benzofuran acids
|
US7332521B2
(en)
|
2003-09-25 |
2008-02-19 |
Wyeth |
Substituted indoles
|
US7141592B2
(en)
|
2003-09-25 |
2006-11-28 |
Wyeth |
Substituted oxadiazolidinediones
|
US7163954B2
(en)
|
2003-09-25 |
2007-01-16 |
Wyeth |
Substituted naphthyl benzothiophene acids
|
US7351726B2
(en)
|
2003-09-25 |
2008-04-01 |
Wyeth |
Substituted oxadiazolidinediones
|
US7534894B2
(en)
|
2003-09-25 |
2009-05-19 |
Wyeth |
Biphenyloxy-acids
|
US7420083B2
(en)
|
2003-09-25 |
2008-09-02 |
Wyeth |
Substituted aryloximes
|
BRPI0417621A
(pt)
*
|
2003-12-17 |
2007-04-10 |
Pfizer Prod Inc |
terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
|
WO2005073205A1
(en)
*
|
2004-01-22 |
2005-08-11 |
Eli Lilly And Company |
Selective estrogen receptor modulators
|
US20080227814A1
(en)
*
|
2004-01-29 |
2008-09-18 |
Jeffrey Alan Dodge |
Selective Estrogen Receptor Modulators
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
US20050203086A1
(en)
*
|
2004-03-04 |
2005-09-15 |
Pfizer Inc. |
Methods of treatment using an EP2 selective receptor agonist
|
EP1732888A1
(en)
|
2004-04-08 |
2006-12-20 |
Wyeth |
Bazedoxifene ascorbate as selective estrogen receptor modulator
|
US20050239798A1
(en)
*
|
2004-04-22 |
2005-10-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for the treatment of premenstrual and other female sexual disorders
|
US7799273B2
(en)
|
2004-05-06 |
2010-09-21 |
Smp Logic Systems Llc |
Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
|
US7444197B2
(en)
|
2004-05-06 |
2008-10-28 |
Smp Logic Systems Llc |
Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
|
JP2008503561A
(ja)
*
|
2004-06-21 |
2008-02-07 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
骨芽細胞機能を刺激するためのpyk2阻害薬
|
CA2576747A1
(en)
*
|
2004-08-17 |
2006-03-02 |
Janssen Pharmaceutica N.V. |
Benzoxazepine derivatives as selective estrogen receptor modulators
|
AU2005277138A1
(en)
|
2004-08-23 |
2006-03-02 |
Wyeth Holdings Corporation |
Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (PAI-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
|
AU2005277137A1
(en)
|
2004-08-23 |
2006-03-02 |
Wyeth |
Pyrrolo-naphthyl acids as PAI-1 inhibitors
|
AU2005277139A1
(en)
|
2004-08-23 |
2006-03-02 |
Wyeth |
Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
|
ES2328384T3
(es)
*
|
2004-11-23 |
2009-11-12 |
Warner-Lambert Company Llc |
Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
|
RU2007121255A
(ru)
|
2005-01-27 |
2009-03-10 |
Вайет (Us) |
Способы и соединения для получения замещенных производных нафтилиндола
|
WO2006114702A2
(en)
*
|
2005-04-25 |
2006-11-02 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
|
EP1899310B1
(en)
|
2005-06-22 |
2010-09-29 |
Pfizer Products Inc. |
Stereoselective hydrogenation process for preparing cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphthalene hydrochloride
|
ES2646326T3
(es)
|
2005-08-03 |
2017-12-13 |
Sprout Pharmaceuticals, Inc. |
Uso de flibanserina en el tratamiento de la obesidad
|
BRPI0614340A2
(pt)
|
2005-08-17 |
2011-04-12 |
Wyeth Corp |
indóis substituìdos e métodos de seu uso
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
JP2009513604A
(ja)
|
2005-10-29 |
2009-04-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
|
US20070105869A1
(en)
*
|
2005-11-08 |
2007-05-10 |
Stephane Pollentier |
Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
JP5212931B2
(ja)
|
2006-01-26 |
2013-06-19 |
学校法人東京理科大学 |
ラソフォキシフェン及びその類縁体の製造方法
|
WO2007128802A2
(en)
*
|
2006-05-09 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
Use of flibanserin for the treatment of post-menopausal sexual desire disorders
|
WO2008000760A1
(en)
|
2006-06-30 |
2008-01-03 |
Boehringer Ingelheim International Gmbh |
Flibanserin for the treatment of urinary incontinence and related diseases
|
US20090318469A1
(en)
*
|
2006-07-14 |
2009-12-24 |
Boehringer Ingelheim International Gmbh |
Use of Flibanserin for the Treatment of Sexual Disorders in Females
|
MX2009001551A
(es)
|
2006-08-14 |
2009-02-20 |
Boehringer Ingelheim Int |
Formulaciones de flibanserina y metodo para fabricarlas.
|
CL2007002214A1
(es)
|
2006-08-14 |
2008-03-07 |
Boehringer Ingelheim Int |
Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
|
EA200900270A1
(ru)
*
|
2006-08-25 |
2009-08-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Системы регулируемого высвобождения и способ их приготовления
|
ES2382009T3
(es)
|
2006-12-01 |
2012-06-04 |
Bristol-Myers Squibb Company |
Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
|
JP5087011B2
(ja)
*
|
2007-01-23 |
2012-11-28 |
馨 井上 |
眼疾患モデル用非ヒト動物
|
CZ2007373A3
(cs)
*
|
2007-05-29 |
2008-12-10 |
Zentiva, A. S |
Zpusob prípravy lasofoxifenu
|
US20090062374A1
(en)
*
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched lasofoxifene
|
CL2008002693A1
(es)
*
|
2007-09-12 |
2009-10-16 |
Boehringer Ingelheim Int |
Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
|
BRPI0818637A2
(pt)
|
2007-10-16 |
2015-04-07 |
Repros Therapeutics Inc |
Métodos de tratamento de sintoma da síndrome metabólica, de glicose em jejum prejudicada, da síndrome metabólica e de redução de níveis de glicose em, jejum em sujeito com hipogonadismo hipogonadotrófico secundário ou idiopático
|
US8003689B2
(en)
*
|
2008-06-20 |
2011-08-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
EP2424839A4
(en)
|
2009-04-29 |
2012-10-17 |
Glenmark Generics Ltd |
PROCESS FOR THE PREPARATION OF LASOFOXIFEN TARTRATE
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
CN102311406A
(zh)
*
|
2010-06-29 |
2012-01-11 |
武汉启瑞药业有限公司 |
拉索昔芬中间体的制备方法
|
CN102464629A
(zh)
*
|
2010-11-12 |
2012-05-23 |
上海医药工业研究院 |
1-{2-[4-(6-甲氧基-2-苯基-3,4-二氢萘-1-基)苯氧基]乙基}吡咯烷的制备方法
|
EP2524908A1
(en)
|
2011-05-20 |
2012-11-21 |
LEK Pharmaceuticals d.d. |
Process for the preparation of alfa-substituted ketones and their application in synthesis of pharmaceutically active compounds
|
DE102011087987A1
(de)
|
2011-12-08 |
2013-06-13 |
Bayer Intellectual Property Gmbh |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
CN102643178A
(zh)
*
|
2012-02-08 |
2012-08-22 |
浙江华海药业股份有限公司 |
一种酒石酸拉索昔芬及其中间体的制备方法
|
EP2819676B1
(en)
|
2012-02-29 |
2018-05-30 |
Repros Therapeutics Inc. |
Combination therapy for treating androgen deficiency
|
CN103113323B
(zh)
*
|
2013-02-05 |
2015-11-11 |
南京华威医药科技开发有限公司 |
酒石酸拉索昔芬中间体的制备方法
|
WO2015092634A1
(en)
*
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
DK3122426T3
(da)
|
2014-03-28 |
2023-04-03 |
Univ Duke |
Behandling af brystcancer ved anvendelse af selektive østrogenreceptormodulatorer
|
US9421264B2
(en)
|
2014-03-28 |
2016-08-23 |
Duke University |
Method of treating cancer using selective estrogen receptor modulators
|
DK3302471T3
(da)
*
|
2015-05-29 |
2021-11-15 |
Eisai R&D Man Co Ltd |
Tetrasubstituerede alkenforbindelser og deres anvendelse
|
JP6920295B2
(ja)
*
|
2015-11-09 |
2021-08-18 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
|
AU2016352592B2
(en)
|
2015-11-10 |
2023-04-27 |
Paracrine Therapeutics Ab |
Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen
|
CN109219604B
(zh)
*
|
2016-04-08 |
2021-09-24 |
豪夫迈·罗氏有限公司 |
四氢异喹啉雌激素受体调节剂及其用途
|
NZ752443A
(en)
|
2016-10-11 |
2022-11-25 |
Univ Duke |
Lasofoxifene treatment of er+ breast cancer
|
JP6346368B1
(ja)
|
2016-11-28 |
2018-06-20 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
インダゾール誘導体の塩及びその結晶
|
CN111801098A
(zh)
|
2018-02-21 |
2020-10-20 |
人工智能治疗公司 |
使用阿匹莫德和谷氨酸能剂的组合疗法
|
CN112261937B
(zh)
|
2018-04-10 |
2023-11-14 |
杜克大学 |
乳腺癌的拉索昔芬治疗
|
CN109317203B
(zh)
*
|
2018-12-03 |
2019-09-03 |
毕云丽 |
一种治疗绝经后妇女骨质疏松症用药物中间体的制备方法
|